Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike
- PMID: 24767986
- PMCID: PMC4109818
- DOI: 10.1016/j.celrep.2014.04.001
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike
Abstract
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection in animal models. Characterized bNAb targets, although key to vaccine and therapeutic strategies, are currently limited. We defined a new site of vulnerability by solving structures of bNAb 8ANC195 complexed with monomeric gp120 by X-ray crystallography and trimeric Env by electron microscopy. The site includes portions of gp41 and N-linked glycans adjacent to the CD4-binding site on gp120, making 8ANC195 the first donor-derived anti-HIV-1 bNAb with an epitope spanning both Env subunits. Rather than penetrating the glycan shield by using a single variable-region CDR loop, 8ANC195 inserted its entire heavy-chain variable domain into a gap to form a large interface with gp120 glycans and regions of the gp120 inner domain not contacted by other bNAbs. By isolating additional 8ANC195 clonal variants, we identified a more potent variant, which may be valuable for therapeutic approaches using bNAb combinations with nonoverlapping epitopes.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
Figures







Similar articles
-
Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.Acta Crystallogr D Biol Crystallogr. 2015 Oct;71(Pt 10):2099-108. doi: 10.1107/S1399004715013917. Epub 2015 Sep 26. Acta Crystallogr D Biol Crystallogr. 2015. PMID: 26457433 Free PMC article.
-
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env.Cell. 2015 Sep 10;162(6):1379-90. doi: 10.1016/j.cell.2015.08.035. Cell. 2015. PMID: 26359989 Free PMC article.
-
Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.J Proteome Res. 2018 Mar 2;17(3):987-999. doi: 10.1021/acs.jproteome.7b00639. Epub 2018 Feb 8. J Proteome Res. 2018. PMID: 29420040 Free PMC article.
-
Antibody epitope exposure and neutralization of HIV-1.Curr Pharm Des. 2010;16(33):3729-43. doi: 10.2174/138161210794079182. Curr Pharm Des. 2010. PMID: 21128886 Review.
-
The HIV glycan shield as a target for broadly neutralizing antibodies.FEBS J. 2015 Dec;282(24):4679-91. doi: 10.1111/febs.13530. Epub 2015 Oct 23. FEBS J. 2015. PMID: 26411545 Free PMC article. Review.
Cited by
-
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug. PLoS Pathog. 2015. PMID: 26267277 Free PMC article.
-
Identification of HIV gp41-specific antibodies that mediate killing of infected cells.PLoS Pathog. 2019 Feb 19;15(2):e1007572. doi: 10.1371/journal.ppat.1007572. eCollection 2019 Feb. PLoS Pathog. 2019. PMID: 30779811 Free PMC article.
-
Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.J Virol. 2018 Jun 29;92(14):e02261-17. doi: 10.1128/JVI.02261-17. Print 2018 Jul 15. J Virol. 2018. PMID: 29618644 Free PMC article.
-
Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.Virology. 2016 Mar;490:17-26. doi: 10.1016/j.virol.2016.01.002. Epub 2016 Jan 21. Virology. 2016. PMID: 26803471 Free PMC article.
-
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Nature. 2015. PMID: 25855300 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous